targeted-protein-stabilization
(3)
Stablix, Inc.
Stablix, Inc. is a preclinical biopharmaceutical company pioneering targeted protein stabilization (TPS), a new therapeutic modality that does the opposite of protein degraders. Its RESTORE platform generates heterobifunctional small molecules called RESTORACs that recruit deubiquitinase enzymes (DUBs) to selectively remove ubiquitin from disease-relevant proteins, restoring deficient proteins to therapeutic levels or correcting aberrant protein function. Co-located in New York City and Boston and founded on science from Columbia University, Stablix has raised roughly $78M and is developing programs in cancer, rare diseases and immunological disorders, including a strategic collaboration with Vertex Pharmaceuticals.
Eddine Saiah
Eddine Saiah, Ph.D., is the CEO and President of Stablix, a preclinical biotechnology company pioneering targeted protein stabilization (TPS) as a new class of small-molecule medicines. A medicinal chemist and drug hunter with more than 25 years of experience, he joined Stablix as Chief Scientific Officer in 2022 and moved into the chief executive role in 2025. His career spans big pharma research leadership at Pfizer and Wyeth, an entrepreneur-in-residence stint at Atlas Venture, and CSO duties at Navitor Pharmaceuticals. He is a co-inventor and author on more than 120 patents and publications, and has helped advance more than a dozen small-molecule candidates into clinical trials.
Tony Kingsley
Tony Kingsley is a biopharmaceutical executive who runs Stablix, Inc., a New York biotech betting that you can treat disease by protecting proteins instead of destroying them. He took the CEO seat in February 2022 after a career of running one drug company after another - Scholar Rock, TARIS Bio, The Medicines Company - and heading global commercial at Biogen, with a McKinsey partnership and a stint in medical devices before that. In July 2025 he joined the board of Indivior. He holds a Dartmouth degree and a Harvard MBA.